SOCS-KIR peptides show promise as cutting-edge therapeutic options for autoimmune disorders, thanks to their small size, stability, and low immunogenicity, which make them favorable candidates for safe therapeutic development. The gene discussed is CISH; the disease is autoimmune disease.